Your 23andMe ATP7B (Wilson Disease) Carrier Result, Explained: What Research Says About Copper, Risk, and Your Kids

Your 23andMe ATP7B (Wilson Disease) Carrier Result, Explained: What Research Says About Copper, Risk, and Your Kids

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: A 23andMe “variant detected” flag for ATP7B usually means you are a healthy carrier, not that you have Wilson disease. Research and clinical guidelines are clear that Wilson disease is autosomal-recessive: you need two faulty copies of ATP7B, one from each parent, to develop it. A single copy makes you a carrier who does not accumulate copper and does not get sick. The disease is diagnosed by copper blood and urine tests and an eye exam, never by a DNA kit alone. And here is the hopeful part: when caught early, treated Wilson disease has a near-normal prognosis. Your real next step as a carrier is reproductive planning and a conversation with a genetic counselor, not panic.

What you’ll learn:

• What a carrier result truly means, and the sharp line between a carrier and someone with the disease.
• How rare Wilson disease is, and how to turn scary numbers into an honest, personal picture.
• How Wilson disease is actually diagnosed, and what a 23andMe or AncestryDNA report can and cannot tell you.
• What today’s treatments are, plus how genetic-privacy laws in the US and Canada protect you.

How Wilson disease is inherited: ATP7B and the carrier-versus-affected line

Wilson disease is a classic single-gene condition, but not the kind most people picture. It is caused by faulty variants in a gene called ATP7B on chromosome 13. It follows an autosomal-recessive pattern, meaning you must inherit a faulty copy from both parents to develop the disease. One faulty copy alone makes you an unaffected carrier. A carrier just means someone who inherited one faulty copy of the gene but stays perfectly healthy.

Think of ATP7B like a pair of matching keys. If even one key works, the door still opens and copper still leaves your liver normally. Only when both keys are broken does copper get stuck and build up. This is the opposite of the dominant conditions many readers have heard of, where a single variant is enough to cause risk.

So what does a 23andMe result actually flag? These carrier-status reports screen a limited set of common ATP7B variants and report carrier status, not disease. In a healthy adult with no symptoms, a “variant detected” result almost always means carrier, not affected. The report is population-level screening information, not a personal diagnosis.

The reproductive math is worth learning. If both you and your partner carry an ATP7B variant, each pregnancy has a 25% chance of an affected child. If only one of you carries a variant, your children cannot have the disease, though some may be carriers themselves. That is why a carrier flag points toward partner testing, not toward personal treatment.

Here is a quick map of what a single carrier result does and does not mean:

• You inherited one faulty ATP7B copy. That makes you a healthy carrier, not a patient.
• You do not accumulate copper. A working second copy keeps copper moving normally.
• Your children are only at risk if your partner also carries a variant. Then each pregnancy has a 25% chance of an affected child.
• The main action is reproductive, not medical. Partner screening and a genetic counselor come first.

One more reason DTC kits can mislead: scientists have cataloged a very large number of ATP7B variants. Over 700 disease-associated variants are documented, and some databases list well over 900. A kit that checks only a handful of common ones can miss rarer mutations entirely. A board-certified genetic counselor is a trained professional who helps you understand what a genetic result means for you and your family. If your result worries you, one can explain exactly what it means; the NSGC directory lists counselors across the US and Canada.

Section recap: Wilson disease needs two faulty ATP7B copies, so one variant makes you a healthy carrier. A 23andMe flag is screening information, and its main meaning for you is reproductive.

Copper metabolism: why a broken ATP7B causes disease (and a carrier stays well)

Copper is essential in small amounts, but toxic in excess. The ATP7B protein is the liver’s copper doorman. It normally moves surplus copper out of liver cells into bile so your body can excrete it, and it helps load copper onto a carrier protein called ceruloplasmin. When both copies of ATP7B fail, that door jams.

With the door jammed, copper piles up first in the liver. Over time it spills into the blood and deposits in the brain, eyes, and other organs. Picture a sink with a blocked drain: water backs up, then overflows onto the floor and into the next room. The overflow is what damages tissue far from the liver.

This explains the two classic ways the disease shows up. The hepatic form brings liver problems such as hepatitis, cirrhosis, and even acute liver failure. The neuropsychiatric form brings tremor, dystonia (sustained muscle contractions), dysarthria (slurred speech), and behavioral or mood changes. Copper deposits in the cornea can also form a green-to-brownish Kayser-Fleischer ring around the iris, a hallmark sign.

There is a neat biochemical clue here. When ATP7B fails to load copper onto ceruloplasmin, the copper-free version of that protein is unstable and breaks down quickly. That is why blood ceruloplasmin often reads low in Wilson disease. That single fact links a gene to a lab test doctors still use today.

Now the reassuring part for a carrier. A person with only one faulty ATP7B copy still has a working doorman, so copper does not accumulate and the disease does not develop. Symptoms of Wilson disease usually appear between ages 5 and 35, though they can fall outside that range. If you have unexplained liver enzyme changes or new neurological symptoms, that warrants prompt evaluation by a physician rather than reassurance from a DNA kit. A hepatologist or neurologist is the right professional to ask.

Section recap: ATP7B is the liver’s copper doorman; losing both copies lets copper build up and damage organs. A carrier keeps a working copy, so copper does not accumulate.

How rare is it, and what does a carrier result mean for your personal risk?

Let’s put the numbers in plain terms. Clinically diagnosed Wilson disease affects roughly 1 in 30,000 people. Carrier frequency in the general population is estimated at about 1 in 90. So carriers are far more common than affected people, which fits a recessive disease where two variants must meet to cause illness.

Here are the key numbers side by side:

Group	Approximate frequency	What it means for you
Carry one ATP7B variant	About 1 in 90 people	Healthy carrier; no personal disease risk
Develop Wilson disease	About 1 in 30,000 people	Two faulty copies; a diagnosed condition
Affected child (both partners carry)	25% per pregnancy	The real question a carrier faces

Here is a subtlety researchers have untangled. Early sequencing analyses suggested biallelic (two-variant) genotypes might occur near 1 in 2,400, far above the roughly 1 in 30,000 who are actually diagnosed. After excluding ATP7B variants predicted to have low penetrance, the revised genetic-prevalence estimate fell to about 1 in 20,000, much closer to observed cases. The gap comes from variable penetrance, meaning some people with two variants stay subclinical or undiagnosed.

Why does that matter for you? Because it proves a key point: population-level variant frequency is not the same as an individual’s disease risk. A single ATP7B variant in an otherwise healthy adult carries essentially no personal risk of developing Wilson disease. Your carrier flag is a statistic about DNA, not a forecast of your health.

Think of it like a fire-safety analogy. Owning one smoke detector battery that works fine does not mean your house is on fire. The real question for a carrier is not “will I get sick?” but “does my partner also carry a variant?” That reframes worry into a concrete, answerable reproductive question.

Penetrance for people who do carry two pathogenic variants is generally high, but the age of onset and severity vary widely. That variability is exactly why diagnosis is never made from a DNA panel alone. It is also why a genetic counselor is the right person to translate a carrier or uncertain result into a personal plan.

Section recap: About 1 in 90 people carry an ATP7B variant, while only about 1 in 30,000 develop the disease. For a healthy single-variant carrier, personal risk is essentially reproductive, not clinical.

Testing in the US and Canada: DTC carrier screening vs. the real diagnostic workup

Start by separating two very different tests. A direct-to-consumer report, such as 23andMe carrier status or third-party interpretation of AncestryDNA raw data, checks selected common ATP7B variants and reports carrier status only. Clinical-grade labs like Invitae and Color sequence the gene far more thoroughly. But for Wilson disease, even a complete gene panel is not the diagnostic tool.

Here is how the two kinds of testing compare:

	DTC carrier screen (23andMe, AncestryDNA raw)	Clinical diagnostic workup
What it checks	A limited set of common ATP7B variants	Ceruloplasmin, 24-hour urinary copper, eye exam, sometimes liver copper
What it reports	Carrier status only, not disease	An actual diagnosis via the Leipzig score
What it cannot do	Rule out rarer variants or diagnose the disease	(It is the real answer, ordered by a doctor)
Who pays	Out-of-pocket	Usually billable to US insurance or provincial plans

Here is the crucial point: Wilson disease is diagnosed biochemically and clinically, not by a single DNA test. The real workup combines low serum ceruloplasmin, an elevated 24-hour urinary copper collection, and a slit-lamp eye exam for Kayser-Fleischer rings. Where needed, doctors add liver copper measurement from a biopsy. Genetic testing is confirmatory, used to support the diagnosis and to screen relatives, not to make the call alone.

Clinicians pull these threads together with the Leipzig diagnostic scoring system, a structured checklist that weighs each finding. Both the American Association for the Study of Liver Diseases (AASLD) 2022 Practice Guidance and the updated EASL-ERN guidelines endorse this combined, multidisciplinary approach. The newer EASL-ERN guideline even adds a parameter called relative exchangeable copper alongside the established criteria. No single test, genetic or biochemical, is diagnostic on its own.

A DNA kit is a weather forecast; the copper tests and eye exam are looking out the window right now. That distinction is why a “variant detected” result is a reason to ask questions, not a reason to assume the worst.

Coverage differs in ways that affect real budgets. Diagnostic labs and hepatology workups are typically billable to US health insurance or Canadian provincial health plans (such as OHIP or RAMQ) when clinically indicated. DTC kits, by contrast, are paid out-of-pocket. NSGC also advises confirming insurance coverage of any genetic counseling or testing before proceeding. Take your result to a physician for the biochemical workup, and to an NSGC-certified genetic counselor for interpretation.

Section recap: DTC kits report carrier status only, while Wilson disease is diagnosed by copper tests plus an eye exam, combined via the Leipzig score. Clinical workups are usually covered; DTC kits are not.

Interpreting your result: carrier status vs. diagnosis vs. uncertain findings

It helps to separate three very different things:

• Carrier result: one variant and, in a healthy adult, essentially no personal disease risk.
• Diagnosis: established only by a physician who combines biochemical, clinical, and genetic evidence.
• Variant of uncertain significance (VUS): a finding the lab cannot yet classify as harmful or harmless.

Confusing these three causes needless panic or false comfort.

Start with the false-comfort trap. A reassuring DTC result does not fully rule out Wilson disease. These panels test only common variants among the 700-to-900-plus that are known. So a “no variant detected” screen cannot promise your ATP7B is entirely normal, especially if you have symptoms. Think of a home test versus a full clinical exam: they are not the same tool.

Now the false-panic trap. A single “variant detected” flag in a symptom-free adult almost always means carrier, not disease. Remember that a carrier does not accumulate copper and does not develop Wilson disease. A carrier result is a reason for reproductive planning and calm follow-up, not a reason to assume your liver is failing.

There is one situation that genuinely warrants urgency. An unexpected ATP7B variant in someone who also has unexplained liver enzyme abnormalities or new neurological symptoms deserves prompt medical evaluation rather than reassurance. In that case, the DNA finding is a prompt to see a doctor quickly, not a diagnosis by itself.

To turn any result into a plan, see the right professionals. An NSGC-certified genetic counselor can contextualize carrier and VUS results and discuss family testing. A hepatologist or neurologist can order the copper workup that gives the real clinical answer. The DNA report is context; the clinic is the verdict.

Section recap: A carrier result is not a diagnosis, and a reassuring DTC screen does not fully rule out Wilson disease. Unexplained liver or neurological symptoms with a variant warrant prompt evaluation.

Prevention, surveillance, and early detection: why timing changes everything

The single most important research message is this: Wilson disease is among the most treatable inherited metabolic disorders when caught before irreversible organ damage. Early detection is the decisive lever. Untreated, the disease can progress to liver failure or permanent neurological injury; treated early, patients can expect a near-normal prognosis.

That is why guidelines emphasize cascade family screening. When one person is diagnosed, AASLD and EASL guidance recommend that first-degree relatives be screened both biochemically and genetically, because presymptomatic treatment prevents disease. A sibling who feels perfectly well today can be protected from ever getting sick if a hidden two-variant genotype is caught early. This is one of the clearest examples in medicine where testing relatives saves lives.

Here is what different people actually need to do:

• A simple single-variant carrier: no copper-restricted diet and no copper surveillance, because a carrier does not accumulate copper. The only actions are reproductive planning and prompting evaluation of any symptomatic relative.
• An affected or at-risk person: ongoing monitoring of liver function and copper levels, plus limiting high-copper foods (shellfish, liver, nuts, and chocolate), especially early in treatment. Checking copper in well water is a sensible extra step for some households.
• A relative of a diagnosed patient: cascade biochemical and genetic screening, because presymptomatic treatment prevents disease.

All of the surveillance above belongs under the care of a hepatologist, not a DNA report. So if you are just a carrier, you can skip the shellfish worry entirely.

Think of it like a recall notice on one part in a car that has two of that part. If only one part is affected, the car runs fine, but the notice is still worth sharing with family members who drive the same model. That is the role of a carrier flag: information to pass along, not a personal alarm.

Section recap: Early detection makes Wilson disease highly treatable, so cascade screening of relatives is life-saving. A simple carrier needs no copper restriction, only reproductive-planning awareness.

The modern treatment landscape and its regulatory status

Standard care rests on two well-established, lifelong strategies. Chelation therapy with penicillamine or trientine binds excess copper so the body can remove it. Zinc salts work differently, blocking copper absorption in the intestine. Guidelines note that chelators are preferred over zinc for significant liver disease, and that treatment choice and monitoring belong to a hepatologist. All of these treat a diagnosed, medically managed condition, never a carrier result.

Here is the current landscape at a glance:

• Chelation (penicillamine, trientine): binds excess copper so the body can remove it; lifelong.
• Zinc salts: block copper absorption in the intestine; lifelong.
• CUVRIOR (trientine tetrahydrochloride): FDA-approved 2022-04-28 for stable, de-coppered adults tolerant to penicillamine.
• Liver transplantation: reserved for acute liver failure or advanced cirrhosis.
• VTX-801 (gene therapy): investigational only; not FDA- or Health Canada-approved and available only in trials.

The newest approved drug is worth knowing by name and date. The FDA approved CUVRIOR (trientine tetrahydrochloride) on 2022-04-28 (NDA 215760) for adults with stable Wilson’s disease who are de-coppered and tolerant to penicillamine. It was described as the first Wilson-disease treatment approved in the United States in more than five decades and holds orphan-drug designation. Its approval was supported by the global phase 3 CHELATE trial, which showed it was non-inferior to penicillamine as measured by non-ceruloplasmin (free) copper. Even so, it is prescribed for a diagnosed condition, never off a DNA or carrier result. Canadian readers should verify current Health Canada availability separately rather than assume access.

For acute liver failure or advanced cirrhosis, liver transplantation can be life-saving and, in effect, corrects the underlying metabolic defect. That is a major surgery reserved for severe disease, decided by a specialist team.

Now the investigational frontier, described honestly. VTX-801 is an experimental gene therapy that uses an AAV vector to deliver a shortened, liver-specific ATP7B “minigene” as a single intravenous infusion, aiming to restore copper metabolism. Interim Phase 1/2 GATEWAY data were presented at the EASL Congress 2024. In the first cohort, they showed increases from baseline in ceruloplasmin ferroxidase activity, a sign the transgene was working, with encouraging early safety. Critically, VTX-801 is investigational only: it is not approved by the FDA or Health Canada, and it is never prescribed based on a genetic result. It is available only through clinical trials. Report any “gene therapy cure” headline you see to your hepatologist for context rather than treating it as an available option today.

Section recap: Lifelong chelation and zinc are the mainstays, with CUVRIOR (trientine tetrahydrochloride, FDA-approved 2022-04-28) the newest agent. Gene therapy VTX-801 is investigational, trial-only, and never prescribed off a DNA result.

Family, GINA, Canada’s law, and the psychosocial reality of a carrier result

Should your children, siblings, or partner test? The answer depends on your situation. For a healthy carrier, the key action is partner carrier screening for reproductive planning, since two carriers have a 25% chance per pregnancy of an affected child. For a family with a diagnosed member, cascade genetic and biochemical screening of first-degree relatives is recommended, because presymptomatic treatment prevents disease. A genetic counselor can help decide who benefits from which test.

On insurance, US protections are real but incomplete. Here is what the law does and does not cover:

• GINA covers: health insurance (Title I) and employment (Title II) — insurers and employers cannot discriminate on genetic information.
• The ACA adds: health insurers cannot use pre-existing conditions, including genetic information, to deny coverage.
• GINA does NOT cover: life insurance, disability insurance, or long-term-care insurance.
• Some US states add: extra protections in those lines beyond GINA, so your location matters.

That life-and-disability gap is a genuine blind spot for anyone with a carrier or risk result. A genetic counselor can help you navigate this nuance before you apply for such coverage.

Canadian readers have their own shield. The federal Genetic Non-Discrimination Act received Royal Assent on 2017-05-04. It prohibits requiring an individual to take a genetic test or to disclose results as a condition of a contract or service, including insurance. There are exceptions for health practitioners and researchers. The Supreme Court of Canada upheld its constitutionality in a 2020 decision under Parliament’s criminal-law power. In some respects it is broader than the US GINA because it extends to goods, services, and contracts.

Finally, it is normal for a carrier flag to cause anxiety, especially with a recently diagnosed relative in the family. The healthy response is to convert worry into a concrete plan. Genetic counseling is designed exactly for this: it turns a scary label into clear, personal next steps. And the guideline-supported message is genuinely reassuring: when Wilson disease is caught and treated early, life expectancy is near-normal.

Section recap: For a carrier, the key step is partner screening; for a diagnosed family, it is cascade testing. GINA and Canada’s law protect against discrimination, but GINA leaves a life-and-disability-insurance gap.

Frequently asked questions

If 23andMe says I’m a carrier for Wilson disease, will I get sick? Almost certainly not from being a carrier. Wilson disease is autosomal-recessive, so you need two faulty ATP7B copies to develop it, and a single-variant carrier does not accumulate copper. In a healthy adult, a “variant detected” flag usually means carrier, not disease. Only the copper workup and an eye exam can give a real clinical answer.

Will my children inherit Wilson disease, and should my partner get tested? Your children can only be affected if both parents pass on a faulty ATP7B copy. If both you and your partner are carriers, each pregnancy has a 25% chance of an affected child. That makes partner carrier screening the most useful next step, ideally with a genetic counselor’s guidance.

Should my siblings get tested if a family member was diagnosed? Yes, this is important. Guidelines recommend cascade screening of first-degree relatives, both genetically and biochemically, because presymptomatic treatment prevents disease. A sibling who feels well today can be protected if a hidden two-variant genotype is found early.

Can a carrier result affect my health or life insurance? In the US, GINA and the ACA protect your health insurance and employment from genetic discrimination. However, GINA does not cover life, disability, or long-term-care insurance. In Canada, the federal Genetic Non-Discrimination Act offers broader protection across contracts, including insurance.

Do I need to avoid copper-rich foods if I’m just a carrier? No. A simple single-variant carrier does not accumulate copper and needs no copper-restricted diet or surveillance. Copper limits (shellfish, liver, nuts, chocolate) apply to people who actually have the disease, especially early in treatment. If you have symptoms, see a doctor rather than changing your diet on your own.

Summary

A 23andMe ATP7B flag usually means you are a healthy carrier, not that you have Wilson disease, because the disease is autosomal-recessive and needs two faulty copies. Copper builds up only when the ATP7B “doorman” fails on both copies, so a carrier does not accumulate copper and does not get sick. About 1 in 90 people carry a variant, while only about 1 in 30,000 develop the disease.

The clinical answer never comes from a DNA kit. Wilson disease is diagnosed by low ceruloplasmin, high urinary copper, and an eye exam, pulled together via the Leipzig score. Treatment is lifelong chelation and zinc, with CUVRIOR (trientine tetrahydrochloride, FDA-approved 2022-04-28) the newest drug; gene therapy VTX-801 remains investigational and trial-only. For a carrier, the real next steps are partner screening and, if a relative is diagnosed, cascade testing that can be life-saving. Legal protections exist in both countries, with a known GINA gap for life and disability coverage. Turn the result into a plan with a genetic counselor and, if needed, a hepatologist.

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH — Wilson Disease. https://www.niddk.nih.gov/health-information/liver-disease/wilson-disease
2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH — Diagnosis of Wilson Disease. https://www.niddk.nih.gov/health-information/liver-disease/wilson-disease/diagnosis
3. MedlinePlus Genetics (NLM), NIH — Wilson disease. https://medlineplus.gov/genetics/condition/wilson-disease/
4. OMIM #277900 (Wilson Disease; WND) and *ATP7B #606882, McKusick-Nathans Institute / NIH. https://omim.org/entry/277900
5. Schilsky ML, Roberts EA, Bronstein JM, et al. A Multidisciplinary Approach to the Diagnosis and Management of Wilson Disease: 2022 Practice Guidance from the AASLD. Hepatology, 2023. https://pubmed.ncbi.nlm.nih.gov/36151586/
6. Schilsky ML, Roberts EA, et al. Wilson disease: a summary of the updated AASLD Practice Guidance. Hepatology Communications, 2023. https://pubmed.ncbi.nlm.nih.gov/37184530/
7. European Association for the Study of the Liver (EASL) and European Reference Network RARE-LIVER. EASL-ERN Clinical Practice Guidelines on Wilson’s disease. Journal of Hepatology, 2025. https://www.journal-of-hepatology.eu/article/S0168-8278(24)02706-5/fulltext
8. Chen C, Shen B, Yang S, et al. Wilson Disease. StatPearls, NCBI Bookshelf, 2024. https://www.ncbi.nlm.nih.gov/books/NBK441990/
9. U.S. Food and Drug Administration / Orphalan SA — FDA Approval of CUVRIOR (trientine tetrahydrochloride) for Wilson disease, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215760s000lbl.pdf
10. Vivet Therapeutics — VTX-801 interim Phase 1/2 GATEWAY data presented at EASL Congress 2024 (Milan); ClinicalTrials.gov NCT04537377. https://www.vivet-therapeutics.com/vivet-therapeutics-presents-interim-data-on-its-phase-1-2-gateway-trial-for-the-treatment-of-wilson-disease-at-easl-congress-2024/
11. Wallace DF, Dooley JS. ATP7B variant penetrance explains differences between genetic and clinical prevalence estimates for Wilson disease. Human Genetics, 2020. https://link.springer.com/article/10.1007/s00439-020-02161-3
12. National Society of Genetic Counselors (NSGC) — Find a Genetic Counselor. https://www.nsgc.org/Find-a-Genetic-Counselor
13. National Human Genome Research Institute (NHGRI), NIH — Genetic Discrimination and the Genetic Information Nondiscrimination Act (GINA). https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination
14. Government of Canada, Justice Laws Website — Genetic Non-Discrimination Act (S.C. 2017, c. 3). https://laws-lois.justice.gc.ca/eng/annualstatutes/2017_3/page-1.html

---

Last updated: 2026-08-10 Author: genelumen editorial team. This article aggregates 14 sources from peer-reviewed medical literature and public health agencies (tier 1=9 / tier 2=5), including the NIH (NIDDK, MedlinePlus/NLM, NHGRI, OMIM), AASLD and EASL-ERN clinical practice guidance, the NSGC, the US FDA, Government of Canada statutes, and PubMed-indexed publications. This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911 (US/Canada) or 119 (Japan). Related: Genetic Diseases category

🌐 日本語版: ウィルソン病（ATP7B）は遺伝する？家族の絶対リスクの読み方